News

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Review top news and interview highlights from the week ending June 6, 2025.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed the implications of a large scale analysis of liso-cel recipients.

The MSKCC Amyloidosis Program director and NEXICART-2 principal study investigator discussed results she presented at ASCO's 2025 meeting.

The hematologist/oncologist at the Cleveland Clinic discussed early results from a clinical trial evaluating the BCMA-directed CAR-T therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The analysis included 153 patients with a median follow-up of 57.8 months.

Following treatment with NXC-201, all 7 patients (100%) showed normalized pathological disease markers.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center, discussed her presentation at ASCO this year.

The associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado discussed an analysis of more than 1,500 patients treated with liso-cel across clinical trials and the real world.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.

The chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Ciltacabtagene autoleucel significantly enhances survival rates in relapsed/refractory multiple myeloma, outperforming standard treatments across various patient subgroups.

The program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center discussed her presentation at ASCO this year.

Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences, discussed the company’s trial design presentation at ASCO’s 2025 meeting.

The chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.

The CAR T-cell therapy showed promise in treating advanced gastric cancer by demonstrating improved survival rates and safety in pivotal trial results.

Review top news and interview highlights from the week ending May 30, 2025.

The chief executive officer and cofounder of March Biosciences discussed the company’s trial design presentation at ASCO’s 2025 meeting.

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

In observance of ALS Awareness Month, held annually in May, we took a look at the clinical pipeline of advanced therapeutics currently in development for the neurodegenerative disease.

Roger Hajjar, MD, the director of the Mass General Brigham Gene and Cell Therapy Institute, also discussed the Institute’s presentations at ASGCT’s 2025 conference.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Alongside the announcement, Ocugen noted that it intends to initiate a phase 2/3 confirmatory clinical trial for OCU410ST in the coming weeks.

Nicholas Giovannone, PhD, a senior principal scientist at Regeneron, also discussed the problem of preexisting immunity caused by natural exposure to AAVs.

The patient’s death occurred after an acute systemic infection and was associated with an unexpected SAE of clinical complications related to capillary leak syndrome.

The treatment under study involves isolating neoantigen-reactive TCRs from patients’ tumor-infiltrating lymphocytes and incorporation into gamma retroviral vectors of the TCR α and β chains.

Review top news and interview highlights from the week ending May 23, 2025.